Please use this identifier to cite or link to this item:
Title: Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study)
Authors: VAN WIJMEERSCH, Bart 
Boyko, Alexey N.
Broadley, Simon
Brassat, David
Dive, Dominique
Hupperts, Raymond M. M.
Lycke, Jan
Montalban, Xavier
Sharrack, Basil
Wray, Sibyl
Margolin, David H.
Chung, Luke
Daizadeh, Nadia
Chirieac, Madalina
Wiendl, Heinz
Issue Date: 2018
Source: NEUROLOGY, 90 (Art N° S15)
Notes: [Van Wijmeersch, Bart] Hasselt Univ, Rehabil, Hasselt, Belgium. [Van Wijmeersch, Bart] Hasselt Univ, MS Ctr Overpelt, BIOMED, Hasselt, Belgium. [Boyko, Alexey N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, Alexey N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Broadley, Simon] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia. [Brassat, David] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, David] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Dive, Dominique] Univ Hosp Ctr Liege, Liege, Belgium. [Hupperts, Raymond M. M.] Maastricht Univ, Med Ctr, Orbis Med Centrum, Sittard, Netherlands. [Lycke, Jan] Univ Gothenburg, Gothenburg, Sweden. [Montalban, Xavier] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Montalban, Xavier] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Toronto, ON, Canada. [Sharrack, Basil] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England. [Wray, Sibyl] Hope Neurol, Knoxville, TN USA. [Margolin, David H.; Chung, Luke; Daizadeh, Nadia; Chirieac, Madalina] Sanofi, Cambridge, MA USA. [Wiendl, Heinz] Univ Munster, Munster, Germany.
Document URI:
ISSN: 0028-3878
e-ISSN: 1526-632X
ISI #: 000453090805104
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Page view(s)

checked on May 20, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.